当前位置：
X-MOL 学术
›
Prostate Cancer Prostatic. Dis.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Diagnostic performance of 18F-PSMA-1007 PET/CT in biochemically relapsed patients with prostate cancer with PSA levels ≤ 2.0 ng/ml.
Prostate Cancer and Prostatic Diseases ( IF 5.1 ) Pub Date : 2019-11-28 , DOI: 10.1038/s41391-019-0194-6 Ewa Witkowska-Patena 1, 2 , Agnieszka Giżewska 1, 2 , Mirosław Dziuk 1, 2 , Jolanta Miśko 2 , Anna Budzyńska 1, 2 , Agata Walęcka-Mazur 3
Prostate Cancer and Prostatic Diseases ( IF 5.1 ) Pub Date : 2019-11-28 , DOI: 10.1038/s41391-019-0194-6 Ewa Witkowska-Patena 1, 2 , Agnieszka Giżewska 1, 2 , Mirosław Dziuk 1, 2 , Jolanta Miśko 2 , Anna Budzyńska 1, 2 , Agata Walęcka-Mazur 3
Affiliation
|
BACKGROUND
The aim of the study was to prospectively evaluate diagnostic performance of 18F-PSMA-1007 PET/CT in patients with prostate cancer (PCa) after radical treatment and low but rising prostate-specific antigen (PSA) levels.
METHODS
We prospectively enrolled 40 consecutive patients after radical treatment (80%-radical prostatectomy, 20%-radiation beam therapy) of PCa and low (0.008 to ≤2.0 ng/ml), rising PSA. Skull to mid-thigh PET/CT imaging was performed 95 (±12) min after injection of 295.5 (±14.1) MBq 18F-PSMA-1007. Detection rate was correlated with PSA levels, Gleason score (GS) and T stage ≥ 3. PET/CT results were verified during 10.3 (±4.7) months follow-up to calculate sensitivity, specificity, negative predictive values (NPV) and positive predictive values (PPV).
RESULTS
18F-PSMA-1007 PET/CT was positive in 24/40 patients, which yielded overall detection rate of 60%. Detection rate was 39%, 55% and 100% for PSA < 0.5, 0.5 to <1.0 and 1.0 to ≤2.0 ng/ml, respectively. PET/CT showed metastases in locoregional lymph nodes in 55% of patients, bones in 36% of patients and local recurrence in 9% of patients. Detection rate was correlated with PSA-a 0.1 ng/ml rise in PSA level increased odds for positive PET/CT by ~30%. PET/CT positivity was independent of GS and T stage. Verification of 40 lesions yielded sensitivity, specificity, PPV and NPV of 100%, 94.4%, 66.7% and 100%, respectively.
CONCLUSIONS
18F-PSMA-1007 PET/CT shows relatively high detection rate in patients with PCa after radical treatment and low, rising PSA levels. Like other PSMA-targeting radiotracers, its detection rate is dependent on PSA levels. 18F-PSMA-1007 also presents excellent sensitivity, specificity and NPV.
中文翻译：
18F-PSMA-1007 PET / CT对PSA≤2.0 ng / ml的前列腺癌生化复发患者的诊断性能。
背景技术本研究的目的是前瞻性评估18F-PSMA-1007 PET / CT在前列腺癌（PCa）接受根治性治疗且前列腺特异性抗原（PSA）水平低但正在上升的患者中的诊断性能。方法我们预期接受40例PCa根治性治疗（80％根治性前列腺切除术，20％放射线治疗）且低PSA（0.008至≤2.0ng / ml）的连续患者。注射295.5（±14.1）MBq 18F-PSMA-1007后95（±12）分钟进行头骨至大腿中段PET / CT成像。检出率与PSA水平，格里森评分（GS）和T期≥3相关联。PET/ CT结果在10.3（±4.7）个月的随访中得到验证，以计算敏感性，特异性，阴性预测值（NPV）和阳性预测值值（PPV）。结果18F-PSMA-1007 PET / CT在24/40患者中呈阳性，总体检测率为60％。PSA <0.5、0.5至<1.0和1.0至≤2.0ng / ml的检出率分别为39％，55％和100％。PET / CT显示55％的患者局部淋巴结转移，36％的患者骨转移和9％的患者局部复发。检测率与PSA相关-PSA水平升高0.1 ng / ml，PET / CT阳性的几率增加约30％。PET / CT阳性与GS和T期无关。验证40个病灶的敏感性，特异性，PPV和NPV分别为100％，94.4％，66.7％和100％。结论18F-PSMA-1007 PET / CT在接受根治性治疗的PCa患者中显示出相对较高的检出率，而PSA水平却较低且不断上升。像其他针对PSMA的放射性示踪剂一样，其检出率取决于PSA水平。18F-PSMA-1007也具有出色的灵敏度，
更新日期：2019-11-28
中文翻译：
18F-PSMA-1007 PET / CT对PSA≤2.0 ng / ml的前列腺癌生化复发患者的诊断性能。
背景技术本研究的目的是前瞻性评估18F-PSMA-1007 PET / CT在前列腺癌（PCa）接受根治性治疗且前列腺特异性抗原（PSA）水平低但正在上升的患者中的诊断性能。方法我们预期接受40例PCa根治性治疗（80％根治性前列腺切除术，20％放射线治疗）且低PSA（0.008至≤2.0ng / ml）的连续患者。注射295.5（±14.1）MBq 18F-PSMA-1007后95（±12）分钟进行头骨至大腿中段PET / CT成像。检出率与PSA水平，格里森评分（GS）和T期≥3相关联。PET/ CT结果在10.3（±4.7）个月的随访中得到验证，以计算敏感性，特异性，阴性预测值（NPV）和阳性预测值值（PPV）。结果18F-PSMA-1007 PET / CT在24/40患者中呈阳性，总体检测率为60％。PSA <0.5、0.5至<1.0和1.0至≤2.0ng / ml的检出率分别为39％，55％和100％。PET / CT显示55％的患者局部淋巴结转移，36％的患者骨转移和9％的患者局部复发。检测率与PSA相关-PSA水平升高0.1 ng / ml，PET / CT阳性的几率增加约30％。PET / CT阳性与GS和T期无关。验证40个病灶的敏感性，特异性，PPV和NPV分别为100％，94.4％，66.7％和100％。结论18F-PSMA-1007 PET / CT在接受根治性治疗的PCa患者中显示出相对较高的检出率，而PSA水平却较低且不断上升。像其他针对PSMA的放射性示踪剂一样，其检出率取决于PSA水平。18F-PSMA-1007也具有出色的灵敏度，
京公网安备 11010802027423号